The clinical significance of oncogene expression in subungual melanoma

British Journal of Plastic Surgery

Volumn 50, Issue 1, 1997, Pages 15-19

  Grover, R ^a   Grobbelaar, A O ^a   Hudson, D A ^b,c   Forder, M ^b   Wilson, G D ^a   Sanders, R ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Department of Plastic Surgery ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MARKER; ONCOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; MALE; MELANOMA; NAIL; ONCOGENE C MYC; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0031034512     PISSN: 00071226     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0007-1226(97)91277-7     Document Type: Article

References (20)

1. Shaw JHF, Koea JB. Acral melanoma in Auckland, New Zealand. Br J Surg 1988; 75: 69-72.
2. Gutman M, Klausner JM, Inbar M, Skornick Y, Baratz M, Rozin RR. Acral melanoma. Br J Surg 1985; 72: 610-13.
3. Leppard B, Sanderson KV, Behan F. Subungual malignant melanoma: difficulty in diagnosis. BMJ 1974; 1: 310-12.
4. Balch CM, Soong SJ, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8,500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous melanoma. 2nd ed. Philadelphia: Lippincott, 1992: 165-87.
5. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-8.
6. Riou GF. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surveys 1988; 7: 442-55.
7. Ross DA, Wilson GD. C-myc oncoprotein expression acts as a prognostic marker in high risk malignant melanoma. Br J Cancer 1994; 69(XXI): 55.
8. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Gen Dev 1993; 3: 44-9.
9. Hedley DW, Freidlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-5.
10. Grover R, Ross DA, Richman PI, Robinson B, Wilson GD. C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Eur J Surg Oncol 1996; 22: 342-6.
11. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
12. Peto R, Pike MC, Armitage P. Design and analysis of clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 1977; 35: 457-81.
13. Saida T, Ohshima Y. Clinical and histopathological characteristics of early lesions of subungual malignant melanoma. Cancer 1989; 63: 556-60.
14. Takematsu H, Obata M, Tomita Y, Kato T, Takahashi M, Abe R. Subungual melanoma: a clinicopathologic study. Cancer 1985; 55: 2725-31.
15. Briggs JC. Subungual melanoma: a review article. Br J Plast Surg 1985; 38: 174-6.
16. Blessing K, Kernohan NM, Park KGM. Subungual malignant melanoma: clinicopathological features of 100 cases. Histopathology 1991; 19: 425-9.
17. Heaton KM, El-Naggar A, Ensign LG, Ross MI, Balch CM. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 1994; 219: 197-204.
18. Grover R, Ross DA, Wilson GD. C-myc oncoprotein: an independent prognostic marker for primary melanoma and its association with tumour antigenicity. Melanoma Research 1995; 5(S1): 17-18.
19. Lazaris AC, Theodoropoulos GE, Aroni K, Saetta A, Davaris PS. Immunohistochemical expression of c-myc oncogene, heat shock protein 70 and HLA DR molecules in malignant cutaneous melanoma. Virchows Arch 1995; 426: 461-7.
20. Versteeg R, Noordermeer IA, Kruse-Walters M. C-myc down regulates class I HLA expression in human melanomas. EMBO Journal 1988; 7: 1023-9.